Qed Therapeutics, A Bridgebio Company

This study tested a drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The drug aims to manage the condition by improving height, but…

This study tested an oral drug called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if the drug could safely increase growth rate by targeting a specific protein involved in bone development. Children who had a…

This study followed 271 children with achondroplasia, aged 2.5 to 17, to track their growth, medical issues, and quality of life over time. No medication or treatment was given. The goal was to better understand the condition and its effects on daily life.